GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gamida Cell Ltd (OTCPK:GMDAQ) » Definitions » ROC (Joel Greenblatt) %

Gamida Cell (Gamida Cell) ROC (Joel Greenblatt) % : 8.91% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Gamida Cell ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Gamida Cell's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 8.91%.

The historical rank and industry rank for Gamida Cell's ROC (Joel Greenblatt) % or its related term are showing as below:

GMDAQ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3387   Med: -411.84   Max: -115.19
Current: -115.19

During the past 8 years, Gamida Cell's highest ROC (Joel Greenblatt) % was -115.19%. The lowest was -3387.00%. And the median was -411.84%.

GMDAQ's ROC (Joel Greenblatt) % is ranked better than
65.8% of 1468 companies
in the Biotechnology industry
Industry Median: -338.875 vs GMDAQ: -115.19

Gamida Cell's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 38.70% per year.


Gamida Cell ROC (Joel Greenblatt) % Historical Data

The historical data trend for Gamida Cell's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gamida Cell ROC (Joel Greenblatt) % Chart

Gamida Cell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -489.93 -333.74 -258.29 -157.19 -115.70

Gamida Cell Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -159.29 -154.00 -152.95 -152.95 8.91

Competitive Comparison of Gamida Cell's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Gamida Cell's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gamida Cell's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gamida Cell's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Gamida Cell's ROC (Joel Greenblatt) % falls into.



Gamida Cell ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.676 + 2.324 + 5.078) - (19.157 + 0 + 0)
=-11.079

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.61 + 1.906 + 4.476) - (17.426 + 0 + 0)
=-9.434

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Gamida Cell for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=4.044/( ( (46.373 + max(-11.079, 0)) + (44.441 + max(-9.434, 0)) )/ 2 )
=4.044/( ( 46.373 + 44.441 )/ 2 )
=4.044/45.407
=8.91 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gamida Cell  (OTCPK:GMDAQ) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Gamida Cell ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Gamida Cell's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Gamida Cell (Gamida Cell) Business Description

Traded in Other Exchanges
N/A
Address
116 Huntington Avenue, 7th Floor, Boston, MA, USA, 02116
Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.
Executives
Jeremy Blank director 6446 DREXEL AVENUE, LOS ANGELES CA 90048
Mary Theresa Coelho officer: Chief Financial Officer 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Ronit Simantov officer: CMO & Chief Scientific Officer 1988 CHAPEL STREET, NEW HAVEN CT 06515
Abigail L. Jenkins director, officer: President and CEO C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE, BOSTON MA 02116
Stephen T Wills director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Ivan M. Borrello director C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Anat Cohen-dayag director C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Naama Halevi-davidov director C/O KALTURA, INC., 250 PARK AVENUE SOUTH, 10TH FLOOR, NEW YORK NY 10003
Joshua F. Patterson officer: General Counsel C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Bio Medical Investment (1997) Ltd. other: Affiliate of 10% Owner 3 AZRIELI CENTER TRIANGLE, TOWER,, 45TH FLOOR, 132 MENACHEM BEGIN ST., TEL AVIV L3 6702301
Shai Lankry officer: Chief Financial Officer C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Ai Gamida Holdings Llc other: Affiliate of 10% Owner 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Ofer Gonen director 1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102
Clal Biotechnology Industries Ltd. other: Affiliate of 10% Owner 3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR, TEL AVIV L3 67023
Len Blavatnik 10 percent owner C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019

Gamida Cell (Gamida Cell) Headlines

From GuruFocus

Q4 2020 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Gamida Cell Ltd Annual Shareholders Meeting Transcript

By GuruFocus Research 02-07-2024

Q3 2022 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Q1 2022 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Gamida Cell Ltd Annual Shareholders Meeting Transcript

By GuruFocus Research 02-07-2024

Gamida Cell Ltd Annual Shareholders Meeting Transcript

By GuruFocus Research 02-07-2024

Q3 2023 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024